VeraChem’s development team present the VM2 protein-ligand binding free energy method at Janssen Pharmaceutical

VeraChem’s development team carry out a presentation of the VM2 protein-ligand binding free energy method at Janssen Pharmaceutical, and make agreement for trial usage of the VM2 software package.

VeraChem’s development team carry out presentation of the VM2 protein-ligand binding free energy method at Dart NeuroScience

VeraChem’s development team carry out a presentation of the VM2 protein-ligand binding free energy method at Dart NeuroScience LLC, and make agreement for trial usage of the VM2 software package.

VeraChem software now licensed to over 500 academic researchers worldwide

VeraChem software now licensed to over 500 academic researchers worldwide

VeraChem’s software now licensed to over 500 academic researchers worldwide.

VeraChem licenses its software

VeraChem licenses its software

VeraChem licenses its novel protein-ligand binding affinity software to a major pharmaceutical company.